{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:31:54Z","timestamp":1791412314671,"version":"4.3.3"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1321,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1111\/j.1365-2133.2011.10658.x","type":"journal-article","created":{"date-parts":[[2011,10,3]],"date-time":"2011-10-03T18:20:02Z","timestamp":1317666002000},"page":"511-517","source":"Crossref","is-referenced-by-count":32,"title":["Comparison of immunological parameters in patients with pemphigus vulgaris following rituximab and IVIG therapy"],"prefix":"10.1093","volume":"166","author":[{"given":"R.J.","family":"Feldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W.G.","family":"Christen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.R.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,1,19]]},"reference":[{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.4049\/jimmunol.159.4.2010","article-title":"Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins","volume":"159","author":"Ishii","year":"1997","journal-title":"J Immunol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1001\/archderm.1996.03890260105016","article-title":"The adjuvant therapy of pemphigus. An update","volume":"132","author":"Bystryn","year":"1996","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1001\/archderm.139.8.1051","article-title":"Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases","volume":"139","author":"Ahmed","year":"2003","journal-title":"Arch Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1586\/eci.11.22","article-title":"Relevance of rituximab therapy in pemphigus vulgaris: analysis of current data and the immunologic basis for its observed responses","volume":"7","author":"Feldman","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1038\/jid.2008.178","article-title":"B-cell depletion immunotherapy in pemphigus: effects on cellular and humoral immune responses","volume":"128","author":"Mouquet","year":"2008","journal-title":"J Invest Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"187864","DOI":"10.1155\/2009\/187864","article-title":"Detection of autoantibodies against recombinant desmoglein 1 and 3 molecules in patients with pemphigus vulgaris: correlation with disease extent at the time of diagnosis and during follow-up","volume":"2009","author":"Belloni-Fortina","year":"2009","journal-title":"Clin Dev Immunol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ophtha.2009.09.049","article-title":"Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report","volume":"117","author":"Foster","year":"2010","journal-title":"Ophthalmology"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1093\/rheumatology\/kel393","article-title":"Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7\u2003yrs","volume":"46","author":"Popa","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-4632.2008.03423.x","article-title":"Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris","volume":"47","author":"Faurschou","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1002\/art.27359","article-title":"Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment","volume":"62","author":"Vital","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"3135","DOI":"10.1200\/JCO.2000.18.17.3135","article-title":"Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin\u2019s lymphoma: safety and efficacy of re-treatment","volume":"18","author":"Davis","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1600-0714.2011.01017.x","article-title":"Rituximab for the treatment of corticosteroid-refractory pemphigus vulgaris with oral and skin manifestations","volume":"40","author":"Craythorne","year":"2011","journal-title":"J Oral Pathol Med"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1002\/art.22019","article-title":"Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis","volume":"54","author":"Roll","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.2741\/2254","article-title":"B cell depletion therapy in autoimmune diseases","volume":"12","author":"Sanz","year":"2007","journal-title":"Front Biosci"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.clim.2006.08.016","article-title":"Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE","volume":"122","author":"Vallerskog","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semarthrit.2008.05.002","article-title":"Serum immunoglobulins and risk of infection: how low can you go?","volume":"39","author":"Furst","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2133.2000.03660.x","article-title":"A study of desmoglein 1 autoantibodies in pemphigus vulgaris: racial differences in frequency and the association with a more severe phenotype","volume":"143","author":"Harman","year":"2000","journal-title":"Br J Dermatol"},{"issue":"Suppl. 1","key":"10.1111\/j.1365-2133.2011.10658.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1159\/000246938","article-title":"Correlation of subclasses of IgG with disease activity in pemphigus vulgaris","volume":"189","author":"Bhol","year":"1994","journal-title":"Dermatology"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1073\/pnas.92.11.5239","article-title":"Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity","volume":"92","author":"Bhol","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1600-0625.2006.00499_1.x","article-title":"Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just \u2018witnesses of disease\u2019?","volume":"15","author":"Amagai","year":"2006","journal-title":"Exp Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaad.2008.09.052","article-title":"A randomized double-blind trial of intravenous immunoglobulin for pemphigus","volume":"60","author":"Amagai","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1067\/mjd.2001.116339","article-title":"Intravenous immunoglobulin therapy in the treatment of patients with pemphigus vulgaris unresponsive to conventional immunosuppressive treatment","volume":"45","author":"Ahmed","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1111\/j.1468-3083.2006.01540.x","article-title":"The role of IVIG treatment in severe pemphigus vulgaris","volume":"20","author":"Baum","year":"2006","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0190-9622(00)90213-5","article-title":"Patterns of remission in pemphigus vulgaris","volume":"42","author":"Herbst","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/j.1365-2133.2011.10658.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.1468-3083.2007.02537.x","article-title":"Outcome of pemphigus vulgaris","volume":"22","author":"Kavusi","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2133.2011.10658.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2133.2011.10658.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T07:02:08Z","timestamp":1686380528000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/166\/3\/511\/6613777"}},"subtitle":["Immunological parameters in patients with PV treated with rituximab and IVIG"],"short-title":[],"issued":{"date-parts":[[2012,1,19]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2133.2011.10658.x","relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1,19]]}}}